title: BCR-ABL(T315I) transcript disappearance in an imatinib-resistant CML patient treated with homoharringtonine: a new therapeutic challenge?
authors.forename: L
authors.initials: L
authors.lastname: Legros
authors.forename: S
authors.initials: S
authors.lastname: Hayette
authors.forename: F E
authors.initials: FE
authors.lastname: Nicolini
authors.forename: S
authors.initials: S
authors.lastname: Raynaud
authors.forename: K
authors.initials: K
authors.lastname: Chabane
authors.forename: J-P
authors.initials: JP
authors.lastname: Magaud
authors.forename: J-P
authors.initials: JP
authors.lastname: Cassuto
authors.forename: M
authors.initials: M
authors.lastname: Michallet
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D001853:Bone Marrow / Q000378:metabolism; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D016044:Fusion Proteins, bcr-abl / Q000096:biosynthesis* / Q000235:genetics*; D015973:Gene Expression Regulation, Leukemic; D006248:Harringtonines / Q000627:therapeutic use*; D000077863:Homoharringtonine; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D010879:Piperazines / Q000494:pharmacology*; D011743:Pyrimidines / Q000494:pharmacology*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D006248:Harringtonines; D010879:Piperazines; D011743:Pyrimidines; D000077863:Homoharringtonine; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl